CoChat

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway

Open access
Bao, Yi, Jiang, Lei, Chen, Haiyan, Zou, Junjie, Liu, Zhimin, Shi, Yongquan · 2015 · Cellular Physiology and Biochemistry

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background/Aims: Glucagon-like peptide-1 (GLP-1)-based drugs are being used to achieve better glucose control in patients with type 2 diabetes, and GLP-1 mimetics such as liraglutide have shown therapeutic potential in preventing diabetes-related microvascular and macrovascular complications as well as comorbidities such as neurodegenerative disorders. In the present study, we investigated the effects of liraglutide on primary rat cortical astrocytes treated with advanced glycation end-products (AGEs). Methods: Gene and protein expression was analyzed by quantitative real time PCR, western blots, and enzyme-linked immunosorbent assay. The caspase-3 activity was assessed using a caspase-3 colorimetric assay kit. The ROS production was measured with CM-H2DCFDA staining. The cell viability of rat astrocytes was determined using MTT assay. Results: Liraglutide ameliorated AGEs-induced oxidative stress, inflammatory cytokine secretion, caspase activation, and cell death in astrocytes, and reversed the AGEs mediated reduction in intracellular cyclic AMP (cAMP) levels, protein kinase A (PKA) activity, and the phosphorylation of the cAMP response element-binding (CREB) protein. The protective effects of liraglutide against AGEs-mediated toxicity were abolished by GLP-1 receptor (GLP-1R) knockdown or pretreatment of cells with the adenylyl cyclase inhibitor SQ22536 or the PKA inhibitor Rp-cAMP. Conclusions: Liraglutide exerts its neuroprotective effects via the GLP-1R-mediated activation of the cAMP/PKA/CREB pathway. The results of the present study support the therapeutic potential of liraglutide for the treatment of neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000430199

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 52 · Cited by 60

Metadata

Authors
Bao, Y., Jiang, L., Chen, H., Zou, J., Liu, Z., & Shi, Y.
Affiliations
Second Military Medical University (CN)
Venue
Cellular Physiology and Biochemistry
Publisher
S. Karger AG
Published
2015
Volume
36
Issue
6
Pages
2366-2378
ISSN
  • 1015-8987 (ISSN-L)
  • 1421-9778
OpenAlex
W2166640400
Cited by
60
References
52
Citations by year
2026: 3 · 2025: 7 · 2024: 3 · 2023: 5 · 2022: 9 · 2021: 10 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 6
FWCI
3.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Cellular Physiology and Biochemistry (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81100584, 81270038)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
liraglutide, GLP-1 receptor, neuroprotection, astrocytes, advanced glycation end products, oxidative stress, cAMP/PKA/CREB pathway, protein kinase A, caspase-3, neurodegenerative diseases, type 2 diabetes, adenylate cyclase
MeSH terms
Liraglutide, Cyclic AMP, Animals, Astrocytes, Signal Transduction, Cytokines, Cell Death, Glycation End Products, Advanced, Rats, Wistar, Cyclic AMP Response Element-Binding Protein, Reactive Oxygen Species, Cyclic AMP-Dependent Protein Kinases, Receptors, Glucagon, Oxidative Stress, Neuroprotective Agents, Inflammation Mediators, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway. https://app.cochat.ai/papers/10.1159/000430199
The paper
Bao, Y., Jiang, L., Chen, H., Zou, J., Liu, Z., & Shi, Y. (2015). The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway. Cellular Physiology and Biochemistry. https://doi.org/10.1159/000430199

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.